Georgios Pongas

Dr. Georgios Pongas


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GPGeorgios Pongas
Georgios Pongas
JRJuan C. Ramos
Juan C. Ramos
The association of human immunodeficiency virus (HIV) and aggressive lymphomas was first reported in 1982. Before the development of effective HIV antiviral therapy, the incidence and the mortality of these lymphomas was high, with patients frequently succumbing to the disease. More lately, the combination of cART with chemoimmunotherapy significantly improved the survival outcome of the HIV-lymphomas. In this review, we discuss on describing the incidence of HIV-associated lymphomas, their clinical features, and the latest advances in the management of the various lymphoma subtypes.

10 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ABAndres Bravo-Gonzalez
Andres Bravo-Gonzalez
MAMaryam Alasfour
Maryam Alasfour
DSDeborah Soong
Deborah Soong
JNJose Noy
Jose Noy
GPGeorgios Pongas
Georgios Pongas
B-cell lymphoid malignancies are a heterogeneous group of hematologic cancers, where Bruton’s tyrosine kinase (BTK) inhibitors have received FDA approval for several subtypes. The first-in-class covalent BTK inhibitor, Ibrutinib, binds to the C481 amino acid residue to block the BTK enzyme and prevent the downstream signaling. Resistance to covalent BTK inhibitors (BTKi) can occur through mutations at the BTK binding site (C481S) but also other BTK sites and the phospholipase C gamma 2 (PLCγ2) resulting in downstream signaling. To bypass the C481S mutation, non-covalent BTKi, such as Pirtobrutinib, were developed and are active against both wild-type and the C481S mutation. In this review, we discuss the molecular and genetic mechanisms which contribute to acquisition of resistance to covalent and non-covalent BTKi. In addition, we discuss the new emerging class of BTK degraders, which utilize the evolution of proteolysis-targeting chimeras (PROTACs) to degrade the BTK protein and constitute an important avenue of overcoming resistance. The moving landscape of resistance to BTKi and the development of new therapeutic strategies highlight the ongoing advances being made towards the pursuit of a cure for B-cell lymphoid malignancies.

13 September 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PCPhilippos Cot
Philippos Cot
AEAndrea Patricia Espejo-Freire
Andrea Patricia Espejo-Freire
KFKenneth Chen Fan
Kenneth Chen Fan
TAThomas Arno Albini
Thomas Arno Albini
GPGeorgios Pongas
Georgios Pongas
Brentuximab vedotin (BV) is an antibody-drug conjugate composed of an anti-CD30 monoclonal antibody conjugated through a linker to the microtubule disturbing agent monomethyl auristatin E (MMAE). B...

1 October 2009 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
GPGeorgios Pongas
Georgios Pongas
RBRonen Ben-Ami
Ronen Ben-Ami
RLRussell Lewis
Russell Lewis
TWThomas J. Walsh
Thomas J. Walsh
Dimitrios P. KontoyiannisDimitrios P. Kontoyiannis
Dimitrios P. Kontoyiannis

18 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ASAli Al Sbihi
Ali Al Sbihi
MAMaryam Alasfour
Maryam Alasfour
GPGeorgios Pongas
Georgios Pongas
Chemoimmunotherapy and cellular therapy are the mainstay of the treatment of relapsed/refractory (R/R) lymphomas. Development of resistance and commonly encountered toxicities of these treatments limit their role in achieving desired response rates and durable remissions. The Antibody–Drug Conjugate (ADC) is a novel class of targeted therapy that has demonstrated significant efficacy in treating various cancers, including lymphomas. To date, three ADC agents have been approved for different lymphomas, marking a significant advancement in the field. In this article, we aim to review the concept of ADCs and their application in lymphoma treatment, provide an analysis of currently approved agents, and discuss the ongoing advancements of ADC development.

1 July 2021 in Blood and Lymphatic Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
GPGeorgios Pongas
Georgios Pongas
BCBruce D. Cheson
Bruce D. Cheson
Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), including the PI3Kδ inhibitor umbralisib and the chimeric antigen receptor–T-cell therapy (CAR-T) axicabtagene ciloleucel. Herein, we present the latest advances in the management of FL, discussing the recently approved therapies in the relapsed and refractory (R/R) setting and various new therapeutic modalities that have the potential to change the treatment landscape and natural history of R/R FL.